Market Cap : 9.88 B | Enterprise Value : 8.43 B | PE Ratio : 16.43 | PB Ratio : 2.29 |
---|
NAS:UTHR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:UTHR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). United Therapeutics's Average Total Inventories for the three months ended in Jun. 2022 was $89 Mil. United Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2022 was $30 Mil. Hence, United Therapeutics's Days Inventory for the three months ended in Jun. 2022 was 273.60.
The historical rank and industry rank for United Therapeutics's Days Inventory or its related term are showing as below:
During the past 13 years, United Therapeutics's highest Days Inventory was 455.12. The lowest was 118.32. And the median was 285.15.
UTHR's Days Inventory is ranked worse thanUnited Therapeutics's Days Inventory increased from Jun. 2021 (223.34) to Jun. 2022 (273.60). It might indicate that United Therapeutics's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year. United Therapeutics's Inventory Turnover for the three months ended in Jun. 2022 was 0.33.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. United Therapeutics's Inventory-to-Revenue for the three months ended in Jun. 2022 was 0.19.
The historical data trend for United Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, United Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, United Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
United Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2021 is calculated as
Days Inventory (A: Dec. 2021 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2020 ) | + | Total Inventories (A: Dec. 2021 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2021 ) | * | Days in Period |
= | ( (86.5 | + | 93.8) | / | 2 ) | / | 122.5 | * | 365 |
= | 90.15 | / | 122.5 | * | 365 | ||||
= | 268.61 |
United Therapeutics's Days Inventory for the quarter that ended in Jun. 2022 is calculated as:
Days Inventory (Q: Jun. 2022 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Mar. 2022 ) | + | Total Inventories (Q: Jun. 2022 )) | / | count ) | / | Cost of Goods Sold (Q: Jun. 2022 ) | * | Days in Period |
= | ( (88.2 | + | 89.9) | / | 2 ) | / | 29.7 | * | 365 / 4 |
= | 89.05 | / | 29.7 | * | 365 / 4 | ||||
= | 273.60 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
United Therapeutics's Inventory Turnover for the three months ended in Jun. 2022 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 29.7 | / | 89.05 | |
= | 0.33 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
United Therapeutics's Inventory to Revenue for the three months ended in Jun. 2022 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 89.05 | / | 466.9 | |
= | 0.19 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of United Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Benkowitz Michael | officer: President and COO | C/O UNITED THERAPEUTICS CORP 1040 SPRING STREET SILVER SPRING MD 20910 |
Maxwell Linda | director | 1040 SPRING STREET SILVER SPRING NC 27709 |
Thompson Tommy G | director | 7711 CARONDELET ST. LOUIS MO 63105 |
Mesa Nilda | director | C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING MD 20910 |
Klein Katherine J | director | STEINBERG HALL-DIETRICH HALL 3620 LOCUST WALK PHILADELPHIA PA 19104 |
Giltner Richard | director | C/O UNITED THERAPEUTICS CORPORTION 1735 CONNECTICUT AVE. NW WASHINGTON DC 20009 |
Olian Judy D. | director | 2000 AVENUE OF THE STARS 12TH FL LOS ANGELES CA 90067 |
Edgemond James | officer: CFO and Treasurer | 1040 SPRING STREET SILVER SPRING MD 20910 |
Zaccardelli David | officer: EVP & Chief Operating Officer | 300 TRI STATE INTERNATIONAL SUITE 272 LINCOLNSHIRE IL 60069 |
Eli Lilly & Co | 10 percent owner | LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285 |
Ferrari John Maxim | officer: CFO & Treasurer | 1110 SPRING STREET SILVER SPRING MD 20910 |
Patusky Christopher | director | |
Hicks Henry Beecher Iii | director | C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910 |
Gray R Paul | director | C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910 |
Dwek Raymond | director |
From GuruFocus
Other Sources
By Zacks 2021-09-03
By Zacks 2021-08-04
By tipranks.com 2022-03-19
By Zacks 2021-06-04
By Zacks 2021-06-17
By Zacks 2022-02-21
By tipranks.com 2022-02-11
By Zacks 2021-12-03
By Zacks 2021-10-19
By Zacks 2021-11-03
By Zacks 2021-11-04
By Zacks 2022-02-16